Evidence map›Paper›PMID 41439231›Full record

ArticleJHLT open2026

Antimicrobial pharmacokinetics and stewardship in critically Ill adult patients receiving ECMO: Challenges, evidence, and future directions.

A L Dzierba, Y-H Liang, H Lyster

Abstract read
In one paragraph

Article in JHLT open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

A L DzierbaDepartment of Medicine, New York University Grossman School of Medicine, New York, NY.
Y-H LiangDepartment of Pharmacy, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.
H LysterDepartment of Pharmacy, Royal Brompton & Harefield Hospitals, part of Guy's & St Thomas' hospital, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Infection is a common indication and complication for extracorporeal membrane oxygenation (ECMO), and adult ECMO recipients face increased nosocomial infection risk. Effective antimicrobial dosing in these patients remains difficult due to pharmacokinetic (PK) and pharmacodynamic (PD) alterations driven by critical illness and extracorporeal circuits. In this narrative review we aim to discuss the potential impact of ECMO on antimicrobial PK and dosing requirements. Findings across studies show heterogeneity in dosing practices and indicate that inter-patient variability is influenced more by critical illness and organ dysfunction than ECMO alone. Standardized dosing protocols remain lacking, and in the absence of robust guidelines, current best practice involves applying PK/PD principles, using therapeutic drug monitoring, and individualizing dosing strategies. Across all antimicrobial drug classes, robust prospective studies linking PK/PD targets to clinical outcomes are lacking. Future research should focus on prospective trials correlating dosing regimens with meaningful clinical endpoints to refine evidence-based antimicrobial guidance. These efforts are essential to developing evidence-based dosing recommendations and optimizing antimicrobial stewardship in this high-risk population.

Indexed as

antibacterialsantifungalsantimicrobial dosingantiviralsextracorporeal membrane oxygenationpharmacodynamicspharmacokinetics

Identifiers

PMID41439231
PMCPMC12721056

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.